Contenuto

Programma Prostata - La produzione scientifica

2009 -2012

  1. Magnani T, Valdagni R, Salvioni R, Villa S, Bellardita L, Donegani S, Nicolai N, Procopio G, Bedini N, Rancati T, Zaffaroni N. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int. 2012 Mar 8.
  2. Pittoni P, Colombo MP. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res 72(4):831-835, 2012.
  3. Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, Valdagni R. Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. Phys Med Biol. 57(5):1399-1412, 2012.
  4. Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ. Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. Eur Urol. 2012 Feb 14. [Epub ahead of print]
  5. Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R. Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. Int J Radiat Oncol Biol Phys. 2011 Oct 8. [Epub ahead of print]
  6. Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, Valdagni R, Vavassori V, Villa S, Fiorino C. Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. Radiat Oncol 24;6:123, 2011.
  7. Becker AL, Orlotti NI, Folini M, Cavalieri F, Zelikin AN, Johnston AP, Zaffaroni N, Caruso F. Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells. ACS Nano 5(2):1335-0344, 2011.
  8. Valdagni R. Prostate cancer units: has the time come to discuss this thorny issue and promote their establishment in Europe? Eur Urol 60(6):1193-1196, 2011.
  9. Valdagni R, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, Rancati T, Avuzzi B, Fiorino C. Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients. Radiother Oncol 101(3):454-459, 2011.
  10. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71(18):5987-5997,2011.
  11. Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol. 100(1):124-30, 2011.
  12. Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 82(5):1957-1966, 2012.
  13. Bellardita L, Donegani S, Spatuzzi AL, Valdagni R. Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. J Oncol Pract. 7(1):e1-5, 2011.
  14. Valdagni R, Albers P, Bangma C, Drudge-Coates L, Magnani T, Moynihan C, Parker C, Redmond K, Sternberg CN, Denis L, Costa A. The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer 47(1):1-7, 2011.
  15. Gandellini P, Folini M, Zaffaroni N. Emerging role of microRNAs in prostate cancer: implications for personalized medicine. Discov Med 9(46):212-218, 2010.
  16. Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, Nicolai N, Capone F, Valdagni R, Bajetta E. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int 108(2):223-227, 2010
  17. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, Valdagni R, Daidone MG, Zaffaroni N. miR-21: an oncomir on strike in prostate cancer. Mol Cancer 21;9:12.2010
  18. Gandellini P, Folini M, Zaffaroni N. Towards the definition of prostate cancer-related microRNAs: where are we now? Trends Mol Med 15(9):381-390, 2009.
  19. Lopergolo A, Zaffaroni N. Biomolecular markers of outcome prediction in prostate cancer. Cancer 115(13 Suppl):3058-3067, 2009.
  20. Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Valdagni R. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol 93(2):197-202, 2009
  21. Van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 105(7):956-962, 2010
  22. Valdagni R, Scardino PT, Denis L. The 2008 European School of Oncology inside track conference, "predictive modeling in prostate cancer". Cancer 115(13 Suppl):3035-3038, 2009
  23. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 69(6):2287-2295, 2009.
  24. Valdagni R, Rancati T, Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer 115(13 Suppl):3141-3149, 2009
  25. Gatta G, Zigon G, Buemi A, Coebergh JW, Colonna M, Contiero P, Denis L, Grosclaude P, Guizard AV, Sanchez-Perez MJ, Plesko I, Ondrusova M, Rachtan J, Valdagni R, Velten M, Vercelli M, Berrino F. Prostate cancer treatment in Europe at the end of 1990s. Acta Oncol. 48(6):867-873, 2009
  26. Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 74(5):1431-1440, 2009
  27. Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, Valdagni R, Calandrino R, Fazio F. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74(2):392-398. 2009

2005-2008

  1. Fiorino C, Rancati T, Valdagni R. Modeling outcome after prostate IGRT. In: Image-guided radiation therapy in prostate cancer. Valicenti RK, Dicker Ap, Jaffray Eds. Informa Healthcare 27-40, 2008
  2. Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, Valdagni R, Fazio F, Calandrino R. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys 71:611-617, 2008
  3. Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori V. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 71: 1065-1073, 2008
  4. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti A, Munoz F, Stasi M, Franzone P, Valdagni R. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 67:1401-1410, 2007
  5. Supino R, Favini E, Cuccuru G, Zunino F, Scovassi AI. Effect of paclitaxel on intracellular localization of c-Myc and p-c-myc in prostate carcinoma cell lines. Ann N Y Acad Sci 1095:175-181, 2007
  6. Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain and analgesic cosumption decrease after samarium infusion: a pilot study. Support Care Cancer 15 (3):339-342, 2007
  7. Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, Pigni A, De Conno F. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Support Care Cancer 15 (10):1177-1184, 2007
  8. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139, 2007
  9. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L. Vaccination therapy in prostate cancer. Cancer Immunol Immunother 56:429-445, 2007
  10. Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Gatta G, Capocaccia R, Valdagni R, De Angelis R. Regional estimates of prostate cancer burden in Italy. Tumori 93: 380-386, 2007
  11. Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S, Daidone MG, Zunino F, Zaffaroni N. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 73: 1703-1714, 2007
  12. Folini M, Bandiera R, Millo E, Gandellini P, Sozzi G, Longoni N, Binda M, Daidone MG, Berg K, Zaffaroni N. Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting hTERT: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Prolif 40:905-920, 2007
  13. Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Casanova Borca V, Girelli G, Mapelli M, Menegotti L, Nava S, Valdagni R. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 70:1130-1137, 2008
  14. Zaffaroni N, Pennati M, Folini M. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small interfering RNAs. Methods Mol Biol 361: 239-264, 2006
  15. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G, Valdagni R, Gabriele P. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol 80:363-370, 2006
  16. Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochem Pharmacol 71:791-798, 2006
  17. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, Zaffaroni N. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5:179-186, 2006
  18. Meli M, Pennati M, Curto M, Daidone MG, Plescia J, Toba S, Altieri D, Zaffaroni N, Colombo G. Small-molecule targeting of heath shock protein 90 chaperone function: rational identification of a new anticancer lead. J Med Chem 49: 7721-7730, 2006
  19. Donegani S et al Rapporto ISTISAN 05/19 "Sperimentazione clinica con radioterapia: profilo etico, radioprotezionistico e specialistico", 2006 (a cura dell'Istituto Superiore di Sanità)
  20. S. Bracarda, O. de Corbelli, C. Greco, T. Prayer-Galetti, R. Valdagni, G. Gatta, F. de Braud, G. Bartsch. Cancer of the prostate. Crit Rev Oncol Hematol 56: 379-396, 2005
  21. Malinverni G, Greco C, Bianchi P, Busutti L, Cagna E, Cozzarini C, Del Duca M, Frezza G, Gabriele P, Genovesi D, Girelli GF, Italia C, Mandoliti G, Mauro F, Nava S, Pratissoli S, Saracino MB, Squillace L, Signor M, Tagliagambe A, Vavassori V, Villa S, Zini G, Valdagni R. Italian survey in posopoerative radiation therapy for prostate carcinoma by the AIRO national working group on prostate radiotherapy: definitive results. Tumori 91: 156-162, 2005
  22. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A. Is the alpha-beta ratio of prostate cancer really low? A prospective, non randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol 75: 74-82, 2005
  23. Fiorino C, Sanguineti G, Valdagni R. Fractionation and late rectal toxicity: No reliable estimates of a/ß value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: In regard to Brenner. Int J Radiat Oncol Biol Phys 62: 289-290, 2005
  24. Valdagni R, Salvioni R, Nicolai N, Villa S, Bedini N, Bajetta E, Procopio G, Donegani S, Bosisio M. In regard to Kagan: "The multidisciplinary clinic". Int J Radiat Oncol Biol Phys 61: 309-310, 2005
  25. Sani M, Viani F, Binda M, Zaffaroni N, Zanda M. Synthesis and in vitro anti-proliferative activity of racemic trifluoro-Casodex (Bicalutamide). Letters in Organic Chemistry 2: 447-449, 2005
  26. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer Interventions. J Cell Mol Med 9: 360-372, 2005
  27. Plescia J., Salz W., Xia F., Pennati M., Zaffaroni N., Daidone M.G, Meli M., Dohi T., Fortugno P., Nefedova Y., Gabrilovoch D., Colombo G., Altieri D.C. Rational design of sheperdin, a novel anticancer agent. Cancer Cell, 7: 457-468, 2005
  28. Folini M., Zaffaroni N. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies. Curr Pharm Des, 11: 1105-1117, 2005
  29. Folini M., Brambilla., Villa R., Gandellini P., Paduano F., Daidone M.G., Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not of hTERTC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer, 41: 624-634, 2005
  30. Begnozzi L, Benassi M, Bertanelli M, Bonini A, Conte L, Cionini L, Fiorino C, Gabriele P, Gardani G, Giani A, Magri S, Morelli M, Morrica B, Olmi P, Orecchia R, Penduzzu G, Raffaele L, Rosi A, Tabocchini MA, Valdagni R, Viti V. Quality Assurance of 3D-CRT: indications and difficulties in their applications. Critical Reviews in Oncology/Hematology 2008
  31. Cozzarini C, Fiorino C, Di Muzio N, Valdagni R, Salonia A, Alongi F, Broggi S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F. Hypofractionated adjuvant radiotherapy with helical Tomotherapy after radical prostatectomy: Planning data and toxicity results of a Phase I-II study. Radiother Oncol 88: 26-33, 2008
  32. Aristei C, Amichetti M, Ciocca M, Nardone L, Bertoni F, Vidali C; Italian Society of Radiation Oncology. Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO). Tumori 94(3): 333-341, 2008
  33. Fiorino C, Alongi F, Broggi S, Cattaneo Mauro G, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, Valdagni R, Fazio F, Calandrino R. Physics aspects of prostate tomotherapy: Planning optimization and image-guidance issues. Acta Oncol 5: 1309-1316, 2008
  34. Iero M, Filippazzi P, Castelli C, Belli F, Valdagni R, Parmiani G, Patuzzo R, Santinami M, Rivoltini L. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumor immunity? Cancer Immunol Immunother 2008
  35. Valdagni R, Scardino PT, Denis L, Kattan MW. Predictive modeling in prostate cancer: a conference summary. Eur Urol 2008
Ultimo aggiornamento: venerdì 20 aprile 2012

Menu di approfondimento

accedi al sito www.adobe.com per scaricare la versione freeware di Acrobat Reader

Per visualizzare documenti in formato PDF è necessario Adobe Reader ®.
Scarica la versione gratuita.